Medicinal cannabis sales in Australia are set to hit a record high, with Australians spending an estimated 400 million dollars in the first half of 2024, double the amount spent in 2023.
Since its legalisation in 2016, the medicinal cannabis industry has grown, with clinics and telehealth services offering more access.
According to the latest National Drug Household Survey, 700,000 Australians used cannabis for medical purposes between 2022 and 2023, with over 200,000 accessing it via prescription.
Data from the Special Access Scheme shows that around 59 per cent of approvals in the first half of this year were for men seeking treatment for chronic pain and anxiety.
The not-for-profit Penington Institute has raised concerns about the quality of care, noting that some clinics prioritise high-volume access over high-quality treatment.
CEO John Ryan stated that the system often reduces patient choice and incentivises prescribers to favour specific products and pharmacies, calling these conflicts unacceptable.